跳至主要内容
临床试验/NCT01880827
NCT01880827已完成1 期

The Effects of Glucose-dependent Insulinotrophic Peptide (GIP) and Glucagon-like Peptide 1 (GLP-1) on Splanchnic Redistribution of Blood Flow at Postprandial State and After Roux-en-Y Gastric Bypass and Sleeve

Turku University Hospital1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
36
试验地点
1
主要终点
Splanchnic blood flow

研究概览

简要总结

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems.

Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.

The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

详细描述

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems, including type 2 diabetes mellitus (T2DM). In T2DM, body is unable to response to circulating insulin levels, which ultimately destroys pancreatic β-cells, leading to chronic hyperglycaemia with ensuing consequences

Intestine is able to produce endocrinologically active substances, which affect to body's intermediary metabolism. One of these substances in glucose-dependent insulinotrophic polypeptide (GIP, part of the incretin family), which potentiates the release of insulin postprandially. However, recent evidence suggests, that GIP may have more harmful than beneficial role in the pathogenesis: it has been shown that GIP participates in the development of insulin resistance, the key defect in the process of metabolic dysfunction. GIP may also regulate postprandial redistribution of splanchnic blood flow which might act in the body's nutrition handling [8].

Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Most established of these procedures is a Roux-en-Y gastric bypass (RYGB), where duodenum and proximal jejunum is bypassed. Clinical and research evidence shows that shortly (before any significant weight loss) after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin¬, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.

Positron emission tomography (PET) is a modern imaging technique, which can be used to study perfusion and metabolism of different organs non-invasively. When radiowater measurement is combined with [15O]CO, both tissues specific perfusion and blood volume can be measured, respectively. When coupled with magnetic imaging (ie. PET-MRI), the volumes-of-interests can be accurately drawn to the desired organs.

The current study is conducted to investigate the vasoactive roles of the GIP. We aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state. Moreover, we hypothesize that the elimination of GIP-effect has a central role in the improved intermediary metabolism observed after bariatric surgery procedures, and that part this change is mediated by changes in splanchnic circulation. Furthermore, we investigate the effect of GLP-1 (glucagon-like peptide 1, another member of incretin family) on splanchnic circulation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • BMI > 35 kg/m2
  • Type 2 diabetes mellitus (fasting glucose more than 7 mmol/l)
  • Age: 18-60 years
  • Previous, carefully planned, conservative treatments for obesity have failed

排除标准

  • BMI over 60 kg/m2
  • Weight more than 170 kg
  • Waist circumference > 150 cm
  • Insulin treatment requiring type 2 diabetes mellitus
  • Mental disorder or poor compliance
  • Eating disorder or excessive use of alcohol
  • Active ulcus-disease
  • Past dose of radiation
  • Presence of any ferromagnetic objects that would make MR imaging contraindicated
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
  • Inclusion criteria for the control group
  • BMI 18-27 kg/m2
  • Age 18-60 years
  • Fasting plasma glucose less than 6.1 mmol/l
  • Normal glucose tolerance test (OGTT)
  • Exclusion criteria for the control group
  • Blood pressure > 140/90 mmHg
  • Any chronic disease
  • Mental disorder or poor compliance
  • Any chronic medical defect or injury which hinder/interfere everyday life
  • Eating disorder or excessive use of alcohol
  • Past dose of radiation
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
  • Presence of any ferromagnetic objects that would make MR imaging contraindicated

研究组 & 干预措施

Royx-en-Y surgery

Active Comparator

Mixed meal test (MMS) with flow studies before and 2 months after the operation

干预措施: GIP-infusion (Drug)

Royx-en-Y surgery

Active Comparator

Mixed meal test (MMS) with flow studies before and 2 months after the operation

干预措施: Roux-en-Y (Procedure)

Royx-en-Y surgery

Active Comparator

Mixed meal test (MMS) with flow studies before and 2 months after the operation

干预措施: MMS (Drug)

Control

Active Comparator

Healthy volunteer group, GIP, GLP-1 and MMS studies

干预措施: GIP-infusion (Drug)

Control

Active Comparator

Healthy volunteer group, GIP, GLP-1 and MMS studies

干预措施: MMS (Drug)

Sleeve gastrectomy

Experimental

Mixed meal test (MMS) with flow studies before and 2 months after the operation

干预措施: GIP-infusion (Drug)

Sleeve gastrectomy

Experimental

Mixed meal test (MMS) with flow studies before and 2 months after the operation

干预措施: MMS (Drug)

Sleeve gastrectomy

Experimental

Mixed meal test (MMS) with flow studies before and 2 months after the operation

干预措施: Sleeve gastrectomy (Procedure)

Control

Active Comparator

Healthy volunteer group, GIP, GLP-1 and MMS studies

干预措施: GLP-1 (Drug)

结局指标

主要结局

Splanchnic blood flow

时间窗: 24 months

Flow is measured using radiowater H2O and PET

次要结局

  • GIP and GLP-1 blood concetrations(24 months)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Pirjo Nuutila

Professor

Turku University Hospital

研究点 (1)

Loading locations...

相似试验